Freedom Investment Management Inc. Sells 1,478 Shares of Pfizer Inc. (NYSE:PFE)

Freedom Investment Management Inc. cut its holdings in Pfizer Inc. (NYSE:PFE) by 7.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 18,945 shares of the biopharmaceutical company’s stock after selling 1,478 shares during the period. Freedom Investment Management Inc.’s holdings in Pfizer were worth $548,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. EverSource Wealth Advisors LLC increased its stake in shares of Pfizer by 39.4% in the first quarter. EverSource Wealth Advisors LLC now owns 25,946 shares of the biopharmaceutical company’s stock worth $665,000 after purchasing an additional 7,331 shares in the last quarter. Bright Futures Wealth Management LLC. purchased a new stake in Pfizer in the 1st quarter worth $321,000. GAMMA Investing LLC lifted its position in shares of Pfizer by 94.7% in the second quarter. GAMMA Investing LLC now owns 26,807 shares of the biopharmaceutical company’s stock valued at $750,000 after acquiring an additional 13,039 shares in the last quarter. Hudson Valley Investment Advisors Inc. ADV boosted its stake in shares of Pfizer by 2.2% in the second quarter. Hudson Valley Investment Advisors Inc. ADV now owns 133,856 shares of the biopharmaceutical company’s stock worth $3,959,000 after acquiring an additional 2,831 shares during the period. Finally, First Financial Bank Trust Division grew its position in shares of Pfizer by 8.4% during the second quarter. First Financial Bank Trust Division now owns 226,869 shares of the biopharmaceutical company’s stock worth $6,348,000 after purchasing an additional 17,495 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insiders Place Their Bets

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The shares were purchased at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares in the company, valued at $282,400. This represents a 11.11 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.06% of the stock is owned by insiders.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Sanford C. Bernstein started coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target on the stock. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, Wolfe Research began coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 target price on the stock. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $32.92.

Pfizer Price Performance

NYSE:PFE opened at $26.21 on Friday. The firm has a market capitalization of $148.53 billion, a price-to-earnings ratio of 35.42, a PEG ratio of 0.70 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The business has a 50 day simple moving average of $27.83 and a 200-day simple moving average of $28.49. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. During the same period in the previous year, the firm earned ($0.17) earnings per share. Pfizer’s quarterly revenue was up 31.2% compared to the same quarter last year. Equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.41%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is currently 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.